アブストラクト
| Title | 免疫調節薬の最適な使用 |
|---|---|
| Subtitle | 特集 Evidence & Consensusで押さえる IBDの治療薬 最新版 基本薬 |
| Authors | 北條紋, 小林拓 |
| Authors (kana) | |
| Organization | 北里大学北里研究所病院炎症性腸疾患先進治療センター |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 12 |
| Page | 2479-2483 |
| Year/Month | 2022 / 9 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●炎症性腸疾患 (IBD) への免疫調節薬は, 維持療法に欠かせない薬剤である. ●ステロイド依存例, カルシニューリン阻害薬による潰瘍性大腸炎治療後, 抗TNFα抗体製剤との併用, 5-ASA製剤不耐例などに使用される. ●用量依存性・非依存性, 短期・長期のさまざまな副作用があり, 近年, 特に短期にみられる重篤な血球減少と脱毛はNUDT15遺伝子多型が原因であることが明らかとなり, 回避することが可能となった. ●免疫調節薬の使用に際しては, 有効性と安全性の両面で十分な知識を得る必要がある. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Bean RH : The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust, 49 : 592-593, 1962
- 2) Derijks LJJ, et al : Review article : thiopurines in inflam-matory bowel disease. Aliment Pharmacol Ther, 24 : 715-729, 2006
- 3) Toyonaga T, et al : Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. J Gastroenterol, 56 : 999-1007, 2021
- 4) Khan KJ, et al : Efficacy of immunosuppressive therapy for inflammatory bowel disease : a systematic review and metaanalysis. Am J Gastroenterol, 106 : 630-642, 2011
- 5) Kobayashi T, et al : Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol, 45 : 1129-1137, 2010
残りの18件を表示する
- 6) Raine T, et al : Immunomodulator and biologic combination therapy in IBD : The debate that just won't go away? J Crohns Colitis, 14 : 1343-1344, 2020
- 7) Severine V, et al : Effectiveness of concomitant immuno-suppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. gut, 56 : 1226-1231, 2007
- 8) Matsumoto T, et al : Adalimumab monotherapy and a com-bination with azathioprine for Crohn's disease : A prospective, randomized trial. J Crohns Colitis, 10 : 1259-1266, 2016
- 9) Yzet C, et al : No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases : A meta-analysis. Clin Gastroenterol Hepatol, 19 : 668-679. e8, 2021
- 10) Yang SK, et al : A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet, 46 : 1017-1020, 2014
- 11) Chaparro M, et al : Safety of thiopurine therapy in inflam-matory bowel disease : long-term follow-up study of 3931 patients. Inflamm Bowel Dis, 19 : 1404-1410, 2013
- 12) Lees CW, et al : Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther, 27 : 220-227, 2008
- 13) Bradford K, et al : Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol, 17 : 4166-4173, 2011
- 14) Beaugerie L, et al : Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease : a prospective observational cohort study. Lancet, 374 : 1617-1625, 2009
- 15) Kobayashi T, et al : Lack of increased risk of lymphoma by thiopurines or biologics in Japanese patients with inflam-matory bowel disease : A large-scale administrative data-base analysis. J Crohns Colitis, 14 : 617-623, 2020
- 16) Fukata N, et al : Hematologic malignancies in the Japanese Presented patients with inflammatory bowel disease. J gastroenterol, 49 : 1299-1306, 2014
- 17) Toruner M, et al : Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology, 134 : 929-936, 2008
- 18) Coelho J, et al : Pregnancy outcome in patients with inflam-matory bowel disease treated with thiopurines : cohort from the CESAME Study. Gut, 60 : 198-203, 2011
- 19) Chang JY, et al : Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol, 18 : 2010-2018. e2, 2020
- 20) Morikubo H, et al : Differential effects of mesalazine for-mulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. J Gastroenterol Hepatol, 36 : 2116-2124, 2021
- 21) Doherty G, et al : European Crohn's and Colitis Organisation topical review on treatment withdrawal['Exit Strategies']in inflammatory bowel disease. J Crohns Colitis, 12 : 17-31, 2018
- 22) Mahmoud R, et al : Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease. Clin Gastroenterol Hepatol, 2022
- 23) Kennedy NA, et al : Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease : relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther, 40 : 1313-1323, 2014
